|
|
Article: New drug treatment for Parkinson's disease.(Azilect from Teva Pharmaceutical Industries Ltd. approved)
- Article from:
- FDA Consumer
- Article date:
- July 1, 2006
CopyrightCOPYRIGHT 2006 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The FDA has approved Azilect (rasagiline), a new drug for the treatment of Parkinson's disease. Azilect is a monoamine oxidase type B (MAO-B) inhibitor that blocks the breakdown of dopamine, a chemical that sends information to the parts of the brain that control movement and coordination.
"This is a welcome development for the more than 50,000 Americans who are each year diagnosed with Parkinson's disease," says Steven Galson, M.D., director of the FDA's Center for Drug Evaluation and Research. "Parkinson's is a relentless disease with limited treatment options, and each new therapy is an important addition to the physicians' treatment options."
...